You are here

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence response
Further thoughts about the ILLUMINATE studies of tabalumab in SLE
Free
  1. David Isenberg
  1. Correspondence to Professor David Isenberg, Division of Medicine, UCL, Centre for Rheumatology Research, London WC1E 6JF, UK; d.isenberg{at}ucl.ac.uk

https://doi.org/10.1136/annrheumdis-2015-208709

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Chiche and colleagues make some very pertinent comments about the apparent failure of Tabalimumab (in the ILLUMINATE trials) set against the ‘deemed’ success of Benlysta (in the BLISS trials) when in fact an analysis of the results indicates that there is little to choose between them.

    I would point out that the least successful …

    View Full Text

    Linked Articles